about ductus biologics
Monoclonal antibodies are a major class of therapeutics with a dozen or more being approved by the FDA every year. These treatments have huge annual revenues, with Humira (treating arthritis) grossing over $20B and Herceptin (treating HER2 breast cancer) grossing over $6B.
The Auctus antibody mimetic platform has significant potential to reduce costs, allowing delivery to a much larger group of patients. Auctus is already in negotiation with some of the major pharmaceutical companies for sale and/or licencing of its technology
